Objectives: This paper offers an overview of the different health care financing policies for incontinence products in 16 European countries and provides health care decision–makers with a framework for positioning their financing policy for incontinence products versus other European countries.Methods: A questionnaire was sent to institutions or persons acquainted with the health care financing system towards incontinence products in 19 countries. Further details were collected by additional telephone interviews and information from several informants. Three countries did not provide information.Results: Financing systems for incontinence products differ widely from country to country. In all countries, hospitalized incontinent patients are better covered than patients residing in institutions for geriatric care. It is furthermore a common phenomenon that patients living at home receive even less coverage. Moreover, most countries apply a fairly uniform type of financing system, meaning that, once assessed in need, financial coverage is very similar for all patients (i.e. not very much differentiated with respect to the nature and severity of their incontinence problems).Conclusion: Given the serious potential impact of incontinence on citizens’ quality of life and given the substantial variations in degree of incontinence, most countries could improve their utilization of (scarce) health care resources devoted to incontinence by developing more ‘selective’ payment policies, whereby reimbursement is ‘tailored’ to patients’ needs.

Keywords:
Incontinence, Reimbursement, Health care financing
1.
Steeman E, Defever M: Urinary incontinence among elderly persons who live at home: A literature review. Nurs Clin North Am 1998;33: 441–455.
2.
Defever M, Kesteloot K, Coucke K, Steeman E, Gruwez T: Socio–Economic Evaluation of Incontinence in Adults, Full Report, Leuven, Katholieke Universiteit, 1997.
3.
Prigent A: Incontinence; Les protections bientìt prises en charge. Monit Pharm 1997;2214.
4.
Hunskar S, Aag H, Kveine E, Daltveit B: Urinary incontinence and health insurance (in Norwegian). Tidsskr Nor Laegeforen 1990; 110:623–625.
5.
Johannesson M, O’Conor RM, Kobelt–Nguyen G, Mattiasson A: Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 80:557–562.
6.
Hellstrom L, Ekelund P, Larsson M, Milsom I: Adapting incontinence patients incontinence aids to their leakage volumes. Scand J Caring Sci 1993;7:67–71.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.